Success Metrics

Clinical Success Rate
80.0%

Based on 8 completed trials

Completion Rate
80%(8/10)
Active Trials
0(0%)
Results Posted
113%(9 trials)
Terminated
2(20%)

Phase Distribution

Ph phase_1
6
60%
Ph phase_2
4
40%

Phase Distribution

6

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
6(60.0%)
Phase 2Efficacy & side effects
4(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

8 of 10 finished

Non-Completion Rate

20.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(8)
Terminated(2)

Detailed Status

Completed8
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
80.0%
Most Advanced
Phase 2

Trials by Phase

Phase 16 (60.0%)
Phase 24 (40.0%)

Trials by Status

completed880%
terminated220%

Recent Activity

0 active trials
Showing 5 of 10
terminatedphase_2

A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC

NCT02387216
terminatedphase_1

Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib

NCT02538627
completedphase_1

Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors

NCT01447225
completedphase_1

A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers

NCT01209195
completedphase_1

A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

NCT01451632
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT02387216Phase 2

A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC

Terminated
NCT02538627Phase 1

Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib

Terminated
NCT01447225Phase 1

Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors

Completed
NCT01209195Phase 1

A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers

Completed
NCT01451632Phase 1

A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

Completed
NCT00734305Phase 1

Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

Completed
NCT00994123Phase 1

A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Completed
NCT01447706Phase 2

A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers

Completed
NCT01151046Phase 2

Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer

Completed
NCT01421472Phase 2

A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10